An efficient route to substituted 1-silacyclopent-2-enes and 1-silacyclohex-2-enes via consecutive 1,2-hydroboration and 1,1-organoboration

The reaction of alkyn-1-yl(vinyl)silanes R₂Si(CCR¹)CHCH₂ [R = Me (1), Ph (2); R¹ = ^tBu (a), Ph (b), SiMe₃ (c)] with 9-borabicyclo[3.3.1]nonane in a 1:1 ratio affords the 1-silacyclopent-2-ene derivatives 4a-c (R = Me) and 5a-c (R = Ph) as a result of selective intermolecular 1,2-hydroboration of the vinyl group, followed by intramolecular 1,1-organoboration of the alkynyl substituent. The analogous reaction sequence converts the alkyn-1-yl(allyl)dimethylsilanes 3a,c into the 1-silacyclohex-2-ene derivatives 7a,c. All reactions were monitored by ²⁹Si NMR spectroscopy and the structural assignment of the final products was based on multinuclear magnetic resonance data (¹H, ¹¹B, ¹³C and ²⁹Si NMR). The molecular structure of 6a was determined by X-ray analysis.     

Synthesis, reactivities and catalytic carbonylation of rhodium(I) carbonyl complexes containing isomeric acetylpyridine ligands

[Rh(CO)₂Cl]₂ reacts with two mole equivalent of 2-acetylpyridine (a), 3-acetylpyridine (b) and 4-acetylpyridine (c) to afford chelate [Rh(CO)Cl(η²-N∩O)] (1a) and non-chelate [Rh(CO)₂Cl(η¹-N∼O)] (1b, 1c) complexes, where, N∩O = a, N∼O = b, c. Oxidative addition (OA) of 1a-1c with CH₃I and C₂H₅I yields penta coordinate rhodium(III) complexes, [Rh(COR)ClI(η²-N∩O)] {R = -CH₃ (2a); -C₂H₅ (3a)} and [Rh(COR)(CO)ClI(η¹-N∼O)] {R = -CH₃ (2b, 2c); -C₂H₅ (3b, 3c)}. Kinetic study for the reaction of 1a-1c with CH₃I indicates a pseudo-first order reaction. The catalytic activity of 1a-1c for the carbonylation of methanol to acetic acid and its ester was evaluated at different initial CO pressures 5, 10 and 20 bar at ∼25 °C and higher turn over numbers (TON = 1581-1654) were obtained compared to commercial Monsanto’s species [Rh(CO)₂I₂]⁻ (TON = 1000) under the reaction conditions: temperature = 130 ± 1 °C, pressure = 15-32 bar, rpm = 450, time = 1 h and catalyst: substrate = 1: 1900.     

Synthesis and characterization of ether-derivatized aminophosphines and their application in C-C coupling reactions

Four new bis(phosphino)amine ligands (Ph₂P)₂N-C₆H₃-R, where R = 3,5-OMe (1), 2,5-OMe (2), 2,4-OMe (3) or 3,4-OMe (4), were prepared via aminolysis of the corresponding dimethoxyanilines with 2 equiv. of diphenylphosphine chloride in the presence of triethyl amine. Oxidation of these ligands with aqueous H₂O₂, elemental S₈ or Se powder afforded the corresponding chalcogen oxides 1a-4a, sulfides 1b-4b and selenides 1c-4c in good yields. Reaction of 1-4 with [MCl₂(cod)] (M = Pt, Pd; cod = cycloocta-1,5-diene) in equimolar ratios afforded cis-[MCl₂{(Ph₂P)₂N-C₆H₃-R}] (M = Pt; R = 3,5-OMe 1d, R = 2,5-OMe 2d, R = 2,4-OMe 3d, and R = 3,4-OMe 4d. M = Pd; R = 3,5-OMe 1e, R = 2,5-OMe 2e, R = 2,4-OMe 3e, and R = 3,4-OMe 4e). Similarly, reaction of [Cu(CH₃CN)₄]PF₆ with the 1-4 in 1:2 ratio gave [Cu{(Ph₂P)₂N-C₆H₃-R}₂]PF₆ (R = 3,5-OMe 1f, 2,5-OMe 2f, 2,4-OMe 3f and 3,4-OMe 4f). All new compounds were fully characterized by spectroscopy and elemental analysis and the molecular structures of seven representative compounds were determined by single-crystal X-ray crystallography. In addition, the palladium complexes were investigated as pre-catalysts in C-C coupling reactions.     

Mixed-ligand tris chelated complexes of Mo(IV) and W(IV): A comparative study

Two hitherto unknown mixed-ligand tris chelated complexes containing 2-aminothiophenolate, [Et₄N]₂[M^IV(NH-(C₆H₄)-S)(mnt)₂] (M = Mo, 1a; W, 2a) and two mixed-ligand tris chelate complex containing N,N-diethyldithiocarbamate, [Et₄N]₂[M^IV(Et₂NS₂)(mnt)₂] (M = Mo, 1b; W, 2b) have been synthesized and characterized structurally. Although these complexes are supposed to be quite similar to the well-known symmetric tris chelate complexes of maleonitriledithiolate (mnt), [Et₄N]₂[M^IV(mnt)₃] (M = Mo, 1c; W, 2c), but display both trigonal prismatic and distorted trigonal prismatic geometry in their crystal structure indicating the possibility of an equilibrium between these two structural possibilities in solution. Unlike extreme stability of 1b, 2b, 1c and 2c, both 1a and 2a are highly unstable in solution. In contrast to one reversible reduction in case of 1b and 2b, 1a and 2a exhibited no possible reduction up to −1.2 V and two sequential oxidation steps which have been further investigated with EPR study. Differences in stability and electrochemical behavior of 1a, 1b, 2a and 2b have been correlated with theoretical calculations at DFT level in comparison with long known 1c and 2c.     

Synthesis and antitumor activity of 5-[1-(3-(dimethylamino)propyl)-5-halogenated-2-oxoindolin-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxamides

We report herein the design and synthesis of novel 1-[3-(dimethylamino)propyl]indolin-2-one derivatives based on the structural features of Sunitinib, a known multitargeted receptor tyrosine kinase inhibitor, and TMP-20, a previously discovered compound with good antitumor activity in our lab. These newly synthesized derivatives were evaluated for in vitro activity against five human cancer cell lines and VEGF/bFGF-stimulated HUVECs. Results revealed that all of the target compounds 1a-p show potent antitumor activity, compounds 1e-h (IC₅₀’s: 0.45-5.08 μM) are more active than Sunitinib (IC₅₀’s: 1.35-6.61 μM), and the most active compound 1h (IC₅₀: 0.47-3.11 μM) is 2.1-4.6-fold more potent than Sunitinib against all five cancer cell lines. In addition, like Sunitinib, 1a-p have higher selectivity on VEGF-stimulated HUVEC other than bFGF-stimulated HUVEC.     

Design of novel N-phenylnicotinamides as selective cyclooxygenase-1 inhibitors

A series of N-phenylnicotinamides (1-40) were designed and evaluated in vitro for their COX inhibitory activities. Most of the synthesized compounds were proved to be potent and selective inhibitors of COX-1. Compound 28 showed the most potent COX-1 inhibitory activity (COX-1 IC₅₀ = 0.68 ± 0.07 μM) and good selectivity (COX-2 IC₅₀ >100 μM). This compound may be useful as a lead compound for superior COX-1 inhibitors. On the basis of the biological results, structure-activity relationships for the COX-1-inhibitory activities of the synthesized N-phenylnicotinamides were discussed concisely.     

Design of potent and selective GPR119 agonists for type II diabetes

Screening of the Merck sample collection identified compound 1 as a weakly potent GPR119 agonist (hEC₅₀ = 3600 nM). Dual termini optimization of 1 led to compound 36 having improved potency, selectivity, and formulation profile, however, modest physical properties (PP) hindered its utility. Design of a new core containing a cyclopropyl restriction yielded further PP improvements and when combined with the termini SAR optimizations yielded a potent and highly selective agonist suitable for further preclinical development (58).     

Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles

The synthesis, biological assessment, and molecular modelling of new tacrine analogues 11-22 is described. Compounds 11-22 have been obtained by Friedländer-type reaction of 2-aminopyridine-3-carbonitriles 1-10 with cyclohexanone or 1-benzyl-4-piperidone. The biological evaluation showed that some of these molecules were good AChE inhibitors, in the nanomolar range, and quite selective regarding the inhibition of BuChE, the most potent being 5-amino-2-(dimethylamino)-6,7,8,9-tetrahydrobenzo[1,8-b]-naphthyridine-3-carbonitrile (11) [IC₅₀ (EeAChE: 14 nM); IC₅₀ (eqBuChE: 5.2 ??M]. Kinetic studies on the easily available and potent anticholinesterasic compound 5-amino-2-(methoxy)-6,7,8,9-tetrahydrobenzo[1,8-b]-naphthyridine-3-carbonitrile (16) [IC₅₀ (EeAChE: 64 nM); IC₅₀ (eqBuChE: 9.6 ??M] showed that this compound is a mixed-type inhibitor (K_i = 69.2 nM) of EeAChE. Molecular modelling on inhibitor 16 confirms that this compound, as expected and similarly to tacrine, binds at the catalytic active site of EeAChE. The neuroprotective profile of molecules 11-22 has been investigated in SH-SY5Y neuroblastoma cells stressed with a mixture of oligomycin-A/rotenone. Compound 16 was also able to rescue by 50% cell death induced by okadaic acid in SH-SY5Y cells. From these results we conclude that the neuroprotective profile of these molecules is moderate, the most potent being compounds 12 and 17 which reduced cell death by 29%. Compound 16 does not affect ACh- nor K⁺-induced calcium signals in bovine chromaffin cells. Consequently, tacrine analogues 11-22 can be considered attractive therapeutic molecules on two key pharmacological targets playing key roles in the progression of Alzheimer, that is, cholinergic dysfunction and oxidative stress, as well as in neuronal cerebrovascular diseases.     

The reactivity of NbX5 (X = F, Cl) with lactons, lactams, and the synthesis of the first nucleobase-containing niobium complex

NbX₅ (X = F, 1a; X = Cl, 1b) reacted with γ-butyrolactone (but), ε-caprolactam (cap), δ-valerolactam (val) in 1:1 M ratio in chlorinated solvent, affording either the neutral coordination adducts NbCl₅L (L = but, 2a; L = val, 2b) or the ionic ones [NbX₄L₂][NbX₆] (X = F, L = but, 3a; X = F, L = val, 3b; X = F, L = cap, 3c; X = Cl, L = cap, 3d). The reaction of 1a with equimolar amount of guanine (gua) in CH₃CN resulted in the formation of the complex [NbF₄(gua)₂][NbF₆], 3e. The addition of two equivalents of organic substrate to 1 gave selectively the compounds NbCl₅L₂ (L = but, 4a; L = val, 4b) or [NbF₄L₄][NbF₆] (L = but, 5a; L = val, 5b; L = cap, 5c). The 1:2 M reaction of 1b with ε-caprolactam proceeded with C-N bond activation and afforded the derivative , 6, in high yield.     

Antioxidant, anti-inflammatory and anti-hyperglycaemic activities of heterocyclic homoprostanoid derivatives

A series of 19 heterocyclic homoprostanoids were synthesized from easily available oleic and ricinoleic acids and evaluated for their possible antioxidant, anti-inflammatory and anti-hyperlipidaemic activities. Compounds with thioxo- and oxoimidazole ring (1) and (2) have shown potent antioxidant activity with IC₅₀ values 0.23 ± 0.09 and 0.41 ± 0.01 mM comparable with standard ascorbic acid. Compound (3) with a quinoxaline ring showed maximum inhibition of BSA denaturation at 1 mM concentration and comparable with standard diclofenac. Incorporation of electron withdrawing substitutions like chloro- and nitro-groups in the quinoxaline ring has resulted in an increase anti-inflammatory activity. Test compounds (3), (3a) and (3c) showed modest inhibition of DPP-IV in vitro. However, the unsubstituted quinoxaline (3) and substituted quinoxalines (3b and 3c) reduced plasma glucose levels indicating the presence of hypoglycemic activity.     

Synthesis and evaluation of 1,5-diaryl-substituted tetrazoles as novel selective cyclooxygenase-2 (COX-2) inhibitors

A series of 1,5-diaryl-substituted tetrazole derivatives was synthesized via conversion of readily available diaryl amides into corresponding imidoylchlorides followed by reaction with sodium azide. All compounds were evaluated by cyclooxygenase (COX) assays in vitro to determine COX-1 and COX-2 inhibitory potency and selectivity. Tetrazoles 3a-e showed IC₅₀ values ranging from 0.42 to 8.1 mM for COX-1 and 2.0 to 200 μM for COX-2. Most potent compound 3c (IC₅₀ (COX-2) = 2.0 μM) was further used in molecular modeling docking studies.     

Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors

A series of phenylimidazole-pyrazolo[1,5-c]quinazolines 1a-q was designed, synthesized and characterised as a novel class of potent phophodiesterase 10A (PDE10A) inhibitors. In this series, 2,9-dimethyl-5-(2-(1-methyl-4-phenyl-1H-imidazol-2-yl)ethyl)pyrazolo[1,5-c]quinazoline (1q) showed the highest affinity for PDE10A enzyme (IC₅₀ = 16 nM).     

Dicarbonyliridium(I) complexes of pyridine ester ligands and their reactivity towards various electrophiles

The reaction of dimeric precursor [Ir(CO)₂Cl]₂ with two molar equivalent of the pyridine-ester ligands (L) like methyl picolinate (a), ethyl picolinate (b), methyl nicotinate (c), ethyl nicotinate (d), methyl isonicotinate (e) and ethyl isonicotinate (f) affords the tetra coordinated neutral complexes of the type [Ir(CO)₂ClL] (1a-f). The single crystal X-ray structure of 1d reveals that the Ir atom occupies the centre of an approximately square planar geometry with two CO groups cis- to each other. Intermolecular C-H?O and Ir?C interactions greatly stabilize the supramolecular structure of 1d in the solid state. The oxidative addition (OA) reactions of 1a-f with different electrophiles such as CH₃I, C₂H₅I and I₂ undergo decarbonylation of one CO group to generate the oxidized products of the type [Ir(CO)RClIL] where R = -CH₃ (2a-f); -C₂H₅ (3a-f) and [Ir(CO)ClI₂L] (4a-f). Kinetic study of the reaction of 1c-f with CH₃I indicates a first order reaction which follow the order 1d > 1c > 1f > 1e. All the synthesized complexes were characterized by elemental analyses, IR, and multinuclear NMR spectroscopy.     

Synthesis and structural characterization of new chiral mixed phosphine phosphoramidite complexes of ruthenium

New phosphoramidite complexes of ruthenium chiral at the metal were synthesized, structurally characterized and their electrochemical and catalytic properties were studied. Reaction of the known chiral phosphoramidites (R = naphthyl, R′ = CH₃, 1a; R = naphthyl, R′ = benzyl, 1b; R = octahydronaphthyl, R′ = benzyl, 1c) with CpRu(PPh₃)₂Cl afforded the title compounds CpRu(PPh₃)(1a-c)(Cl) (2a-c) in 46-74% isolated yields. Fractional crystallization of 2b and 2c afforded the corresponding diastereopure complexes which are chiral both at the metal and at the ligand. The molecular structures of 2b and 2c were determined, revealing a pseudo octahedral coordination geometry about the ruthenium center. Electrochemical studies by cyclic voltammetry showed reversible electrochemical behavior of the metal complexes 2a-c. The new metal complexes are catalytically active in the Mukaiyama aldol reaction (24 h, room temperature, 31-53% yield), but almost no enantiomeric excesses for the products were obtained.     

Design, synthesis, and evaluation of bromo-retrochalcone derivatives as protein tyrosine phosphatase 1B inhibitors

A series of bromo-retrochalcones was designed, synthesized and evaluated as PTP1B inhibitors based on licochalcone A and E. Compounds 6, 12, 13, 14, 25, 36, 37, 39, and 41 showed potent inhibitory effects against PTP1B, and compound 37, the most potent among the series, had an IC₅₀ value of 1.9 μM, about two-fold better than that of the positive control, ursolic acid.     

Transition metal halide salts of 8-methylquinolinium: Synthesis and structures of (8-methylquinolinium)2 MX4·nH2O (M = Cu, Co, Zn; X = Cl, Br; n = 0, 1)

The reactions of metal(II) chlorides and bromides with 8-methylquinoline (8-mequin) in neutral and acidic solutions were investigated. The reaction with ZnCl₂, ZnBr₂, CoCl₂, CoBr₂, CuCl₂ or CuBr₂ with the appropriate HX in water or aqueous ethanol gave complexes of the formula (8-mequin)₂MX₄ (1, M = Cu, X = Cl; 2, M = Cu, X = Br; 3, M = Co, X = Cl; 4, M = Co, X = Br) or (8-mequin)₂ZnX₄·nH₂O (5, X = Cl, n = 0; 6, X = Br, n = 0; 7, X = Cl, n = 1; 8, X = Br, n = 1). Crystals of 1, 2 and 4-8 suitable for single crystal X-ray diffraction were obtained and the structures reported. Compounds 1 and 2 crystallize in the monoclinic space group C2/c, while 4-8 crystallize in the triclinic space group, . Variable temperature magnetic susceptibility data indicate very weak interactions for the copper compounds 1 and 2, while the magnetic behavior of 3 and 4 is dominated by single ion anisotropy, with weaker antiferromagnetic interactions.     

Antitumor agents 279. Structure-activity relationship and in vivo studies of novel 2-(furan-2-yl)naphthalen-1-ol (FNO) analogs as potent and selective anti-breast cancer agents

In our ongoing modification study of neo-tanshinlactone (1), we discovered 2-(furan-2-yl)naphthalen-1-ol (FNO) derivatives 3 and 4 as a new class of anti-tumor agents. To explore structure-activity relationships (SAR) of this scaffold, 18 new analogs, 6-12 and 14-24, were designed and synthesized. The C11-esters 7 and 12 displayed broad anti-tumor activity (ED₅₀ 1.1-4.3 μg/mL against seven cancer cell lines), while C11-hydroxymethyl 14 showed unique selectivity against the SKBR-3 breast cancer cell line (ED₅₀ 0.73 μg/mL). Compounds 15 and 22 displayed potent and selective anti-breast tumor activity (ED₅₀ 1.7 and 0.85 μg/mL, respectively, against MDA-MB-231). The SAR results demonstrated that the substitutions from the ring-opened lactone ring C of 1 are critical to the anti-tumor potency as well as the apparent tumor-tissue type selectivity. Treatment with 3 in Brca1^f11/f11p53^f5&6/f5&6Cre^c mice models significantly inhibited the proliferation of mammary epithelial cells and branching of mammary glands.     

Discovery of a potent and selective small molecule hGPR91 antagonist

GPR91, a 7TM G-Protein-Coupled Receptor, has been recently deorphanized with succinic acid as its endogenous ligand. Current literature indicates that GPR91 plays role in various pathophysiology including renal hypertension, autoimmune disease and retinal angiogenesis. Starting from a small molecule high-throughput screening hit 1 (hGPR91 IC₅₀: 0.8 μM)—originally synthesized in Merck for Bradykinin B₁ Receptor (BK₁R) program, systematic structure-activity relationship study led us to discover potent and selective hGPR91 antagonists e.g. 2c, 4c, and 5g (IC₅₀: 7-35 nM; >1000 fold selective against hGPR99, a closest related GPCR; >100 fold selective in Drug Matrix screening). This initial work also led to identification of two structurally distinct and orally bio-available lead compounds: 5g (%F: 26) and 7e (IC₅₀: 180 nM; >100 fold selective against hGPR99; %F: 87). A rat pharmacodynamic assay was developed to characterize the antagonists in vivo using succinate induced increase in blood pressure. Using two representative antagonists, 2c and 4c, the GPR91 target engagement was subsequently demonstrated using the designed pharmacodynamic assay.     

Structural studies on 1:1 and 2:1 adducts of silver(I) cyanide with alkanediamine ligands

The crystal structures of two 1:1 ligand-silver(I) cyanide complexes, [Ag(CN)(en)] (en = ethane-1,2-diamine) (1) and [Ag(CN)(pn)] (pn = propane-1,2-diamine) (2), and of two 2:1 ligand-silver(I) cyanide compounds, [(AgCN)₂ · tn] (tn = propane-1,3-diamine) (3) and [(AgCN)₂ · bn] (bn = butane-1,4-diamine) (4), were determined from single-crystal X-ray diffraction data, collected at 173 K. In 1 and 2, mononuclear AgCN complexes are formed, in which silver(I) is coordinated by one cyanide and one chelating alkanediamine donor ligand. However, in the dinuclear adducts of 3 and 4, two AgCN units are connected by one alkane-1,n-diamine bridging ligand (n = 3, 4). The resulting molecules of 1-4 are cross-linked via N-H?N hydrogen bonds. Apart from these intermolecular contacts, comparatively short Ag(I)-Ag(I) distances of 3.182(1) Å (in 1), 3.267(1) Å (in 2), 3.023(2) Å (in 3) and 3.050(2) Å (in 4) occur.     

X-ray powder and single crystal structures of two unprecedented families of bpca-based 1-D magnetic chains (Hbpca = bis(2-pyridylcarbonyl)amine)

Two unprecedented families of bpca-based mono-dimensional complexes Cu(bpca)(X) (X = CN, 1; N₃, 2) and [Cu_1 − xFe_x(bpca)](ClO₄) (x = 0, 3; 0.23, 4) were synthesised. The structure of 1 was solved ab initio from X-ray powder diffraction data and refined by Rietveld methods. The complexes 3-4 were characterised by X-ray single crystal diffraction. In 1 the cyano ligand coordinates the metal centres, the Cu centres forming a zigzag 1-D chain along the (0 0 1) direction, while in 3-4, the bpca ligand itself acts as the link towards the metal ions which are arranged in a linear 1-D chain running parallel to the (0 0 1) direction. An infrared spectroscopy study confirmed these coordination modes. The magnetic properties of both chain families were studied. 1-2 do not show significant magnetic interactions, whereas the magnetic behaviour for 3-4 suggests dominant antiferromagnetic interactions between the metal ions within the chains. The magnetic behaviour of 3 was analysed using the Padé approximation of the Bonner-Fisher model for S = 1/2 antiferromagnetic chains. The J value was estimated as 10 K.